Response to Induction Chemotherapy for Locally Advanced Nasopharyngeal Cancer to Predict Prognostic Impact of Chemosensitivity.

Jiade J. Lu,Xiaoshuang Niu,Xiaoming Ou,Fei Liang,Chaosu Hu,Lin Kong
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.6033
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:6033 Background: Nasopharyngeal cancer (NPC) is highly sensitive to chemotherapy and radiotherapy, and concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced NPC (LA-NPC).The effectiveness of platinum-based induction chemotherapy (ICT) with novel agent(s)such as taxane on overall or disease-free survival has been suggested in prospective trials. The purpose of this study is to evaluate the clinical value of observed response to ICT in predicting treatment outcome in patients with LA-NPC. Methods: Between 4/2007 and 8/2014, 687 patients with LA-NPC(i.e., T3, T4, or N+) were treated with platinum-based ICT(100 patients with taxane +/-5FU or gemcitabine [TP/TPF/GP], and 17 with 5FU [PF]) and evaluated for response with MRI were identified. Among the 120 patients who had stable disease (SD) or progression (PD) after ICT (ICT-resistant), 117 were successfully matched for diagnosis/follow-up time, gender, TNM stage, ICT regimen, CRT regimen (none vs. low vs. high dose cisplatin vs. targeted agents), and adjuvant chemotherapy (none vs. TP/TPF/GP vs. PF) to 117of the remaining 567 patients who achieved complete or partial response (CR or PR) after ICT (ICT-sensitive) by propensity score analysis. Results: The median follow-up time was 34 months (range 3-97 months). The overall survival (OS), progression-free survival (PFS), and local/regional/distant-metastatic relaps free survival (LRFS/RRFS/DMFS) rates were significantly better in the ICT-sensitive group (Table). Conclusions: Response to ICT is a significant predictive factor not only for OS, PFS, and DMFS but also for locoregional disease control in patients with LA-NPC. Prospective study is needed to confirm such findings then evaluate whether more aggressive CRT and/or adjuvant chemotherapy regimens may improve the prognosis of the ICT-resistant LA-NPC patients. Treatment outcomes in ICT-sensitive vs ICT-resistant LA-NPC patients. 3-year (%) 5-year (%) P value ICT-resistant ICT-sensitive ICT-resistant ICT-sensitive OS 79.3 94.9 66.1 84.2 0.006 PFS 47.1 86.4 31.1 72.8 <0.001 LRFS 73.0 57.6 97.9 94.4 <0.001 RRFS 80.8 80.8 97.5 97.5 <0.001 DMFS 77.2 66.9 90.8 76.2 0.005
What problem does this paper attempt to address?